Eculizumab is a recombinant humanised monoclonal antibody. It prevents complement-mediated lysis of PNH red blood cells which are abnormally sensitive to destruction.
Eculizumab achieves this by specifically binding to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.
This results in decreased haemolysis, decreased transfusions and a reduction in occurrence of thrombosis in PNH patients.
Further information: Alexion 01483 246641